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Introduction: IL-17 has a putative role in the pathophysiology of Sjogren’s syndrome (SS) and has been shown to
be upregulated in the salivary glands of affected individuals. Sequestration of IL-17 with Adenoviral-mediated gene
therapy has previously shown a benefit upon the SS-like phenotype in the Aec1/Aec2 mouse model. We sought to
understand the proteomic consequences of IL-17 sequestration in the salivary gland of this mouse model as a
means of illuminating the role of IL-17 in SS-like disease.
Methods: Ultrasound-assisted gene transfer (UAGT) was utilized to express a fusion protein composed of the
extracellular portion of the IL-17 receptor fused to fragment of crystallization (Fc) in the submandibular glands of
Aec1/Aec2 mice at 8 weeks of age. After confirming expression of the fusion protein and local and systemic
sequestration of IL-17, proteomic profiling was performed on submandibular glands of a treated cohort of
Aec1/Aec2 animals relative to the background strain and sham-treated animals.
Results: The most notable proteomic signatures of IL-17 sequestration on SS-like disease-related proteins were
Kallikrein-related peptidases, including the putative autoantigen Klk1b22. IL-17 sequestration also notably led to an
isoelectric shift, but not a molecular weight shift, of Kallikrein-1, attributed to phosphorylation.
Conclusion: Non-viral IL-17 sequestration gene therapy in the salivary gland is feasible and downregulates
expression of a putative SS autoantigen in the Aec1/Aec2 mouse.Introduction
Sjogren’s syndrome (SS) is a systemic autoimmune disease
affecting multiple organ systems and is the second most
common rheumatic illness in the USA, affecting approxi-
mately 4 million Americans, 90 % of whom are female.
The most common manifestations of SS are dry eyes and
dry mouth, due to the characteristic exocrinopathy affect-
ing the salivary and lacrimal glands. Despite the systemic
comorbidities of SS, the disease has historically and prac-
tically been classified as a dry mouth/dry eye condition,
leading the American College of Rheumatology to issue
diagnostic guidelines focused on these two symptoms [1].* Correspondence: mpassine@wpahs.org
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creativecommons.org/publicdomain/zero/1.0/The molecular etiology of SS is poorly understood and
appears to be very complex, based upon the findings
that a variety of signaling pathways have been shown to
be dysregulated in human salivary gland biopsies and
animal models. SS appears to have a variable polygenetic
basis [2], and thus patient-to-patient disease heterogen-
eity may explain the difficulty researchers have encoun-
tered in the search for a common cellular or molecular
pathobiology in SS. At present, research efforts to un-
ravel SS tend to focus on mechanisms underlying
lymphocytic infiltration of the salivary gland, as such in-
filtration is pathognomonic and thus a reasonable candi-
date for an advanced deleterious state upon which
multiple pathways converge.
In this research context, and in the absence of effective
therapies for SS, gene therapy has been proposed as a
means of disrupting the pathobiological cascade leadinge distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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destruction. For such an approach to be successful, a
gene drug capable of disrupting the pathobiology of SS
at a convergence point proximal to lymphocytic infiltra-
tion of the salivary gland is required. Previous reports
embodying this concept have utilized viral vector sys-
tems to deliver human vasoactive intestinal peptide [3],
IL-27 [4], and cytotoxic T-lymphocyte antigen 4 [5], each
showing beneficial effects upon Sjogren’s-like disease in
animals models.
All previous demonstrations of gene therapy in animal
models of SS have utilized a virus as the gene transfer
vector. This approach is efficient and provides important
proof of principle, but the clinical practicality of infusing
a virus into the salivary gland to treat SS may not be op-
timal, as host immune response to the viral vector may
contribute negatively to disease progression [6]. As an
alternative, our group has developed and successfully
demonstrated ultrasound-assisted gene transfer (UAGT)
to the salivary gland using a combination of microbub-
bles and low frequency ultrasound that produces a sono-
poration effect, allowing efficient entry of non-viral
vectors into the cells of the salivary gland.
The present study sought to dissect the molecular
basis of the impressive therapeutic effects of IL-17 se-
questration reported in Nguyen et al. [7], who showed
that sequestration of IL-17 by using Adenoviral gene
transfer to express a fusion protein called IL-17R:Fc im-
proves function and histological metrics in the Aec1/
Aec2 model of SS [7]. This fusion protein is formed
from the soluble portion of the IL-17 receptor fused to
fragment crystallizable region (Fc), yielding a molecule
that can efficiently bind and sequester free IL-17. This
same group had earlier shown that adenoviral-mediated
expression of IL-17A in healthy, non-SS-prone mice in-
duces an SS-like disease [8]. IL-17 is a particularly inter-
esting therapeutic target in SS both due to the putative
role of IL-17 secreting T cells in the human disease, and
the availability of emerging anti-IL-17 monoclonal anti-
bodies as approved agents in other rheumatic diseases.
Using UAGT to deliver the IL-17R:Fc cDNA to the
Aec1/Aec2 mouse, we sought to compare the proteomic
profiles of salivary gland tissue from IL-17R:Fc-treated
animals, control animals treated with an irrelevant Lucif-
erase (Luc) gene, and the background strain. Our hy-
pothesis was that IL-17R:Fc gene therapy would shift the
proteomic profile of the salivary gland of Aec1/Aec2 ani-
mals closer to that of the background strain, relative to
Luc-treated animals.
Methods
Animals, husbandry, and experimental group design
The Institutional Animal Care and Use Committee of
Allegheny Health Network Research Institute approvedall animal experimentation described herein. The C57
BL/6.NOD-Aec1 Aec2 mouse line [9] was acquired as a
kind gift from Dr Ammon Peck (University of Florida,
Gainesville, FL, USA) and mice were genotyped to
confirm their identity using the probes: D3Mit151-F:
5′-GGTAAAATATTTTCTGGGCAAGC, D3Mit151-R:
5′-TTGTTAATTGTAATTCTGTTTCTGTCG. All gene
transfer was performed on animals at 8 weeks of age.
A total of 48 mice were utilized in this study. One co-
hort of Aec1/Aec2 mice (n = 33) was assigned for deter-
mination of relative levels of IL-17R:Fc transcript and
local and systemic levels of IL-17 protein. These animals
received the following treatments: naïve (n = 2), UAGT/
IL17R:Fc (n = 4), AdIL17R:Fc 1 × 107 viral particles (vp)
(n = 4), AdIL17R:Fc 1 × 108 vp (n = 5), and AdIL17R:Fc
1 × 109 vp (n = 5) and were sacrificed 48 hours after
gene transfer. A second cohort (n = 15) was utilized for
proteomic profiling of submandibular glands following
gene transfer. These Aec1/Aec2 animals received the fol-
lowing treatments: UAGT/Luc (n = 5) and UAGT/
IL17R:Fc (n = 5). A third group in this cohort (n = 5)
were C57/BL6 background strain animals who received
sham gene transfer consisting of anesthesia and ductal
cannulation.
Vector design and preparation
The plasmid vectors pCMV-GL3 (Luc) have been previ-
ously described by our group [10] and were used to gen-
erate the pCMV-IL17R:Fc vector, ensuring both vectors
were isogenic with respect to the backbone. The adeno-
viral vector expressing IL-17R:Fc (AdIL17R:Fc) was ac-
quired as a kind gift from Dr Jay Kolls (University of
Pittsburgh, Pittsburgh, PA, USA) and was upscaled and
purified using standard methods previously described by
our group [11]. The cDNA for the IL-17R:Fc fusion pro-
tein was generated from adenoviral genomic DNA, se-
quence verified, and cloned into pCMV-GL3, replacing
the GL3 sequence with the IL-17R:Fc sequence. Plasmid
vectors were upscaled by growing in DH5α-competent
cells (Life Technologies, Carlsbad, CA, USA) and vectors
were purified using CsCl gradient ultracentrifugation.
Salivary gland gene transfer
At 8 weeks of age, Aec1/Aec2 animals or background
C57/BL6 animals received gene transfer to the subman-
dibular glands bilaterally via UAGT or adenovirus.
UAGT was performed as we have previously described
[10]. Briefly, animals were anesthetized with a mixture of
ketamine and xylazine and the submandibular duct was
cannulated bilaterally, then 50 μl of solution containing
either the adenoviral vector or 15 % v/v Definity micro-
bubbles and 1 μg/μl of plasmid vector in normal saline
was infused. Bubbles were destroyed by four 30-s bursts
from a Sonigene device (Visualsonics, Inc., Toronto, ON,
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with 10 s between pulses. Following the four pulses, the
transducer was withdrawn and the animal was rested for
10 minutes before the catheter was removed.
IL-17R:Fc transcript and IL-17 protein detection in
submandibular glands
At 48 hours after gene transfer, animals were sacrificed
by cervical dislocation and submandibular glands re-
moved and homogenized in RNALater. Total RNA was
isolated from homogenized tissue using the RNEasy
protocol (Qiagen, Venlo, Limburg Netherlands) and
cDNA synthesized using a first strand synthesis kit
(Roche Life Sciences, Indianapolis, Indiana USA). IL-17R:Fc
transcript levels were determined by CYBR green quan-
titative real-time reverse transcription PCR using mouse
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
transcription level as an internal control on a RocheA 
B
Fig. 1 Local IL-17 sequestration following IL-17R:Fc gene transfer to the sal
fusion protein following gene transfer with varying amounts of an adenovi
gene transfer (UAGT)/IL-17R:Fc (n = 4). Error bars are + standard error of the
UAGT/IL-17R:Fc relative to UAGT/Luciferase (Luc) and the background strain
housekeeping controlLightCycler® 480. The following primers were used: IF-
17R:Fc-F: 5′-ATGGCTGCTTCTGCTGCT, IL-17R:Fc-R:
5′- CTTGACTCTGCAGCTCAGCC -3′ GAPDH-F: 5′-
CGTCCCGTAGACAAAATGGT, GAPDH-R: 5′- TTGA
TGGCAACAATCTCCAC. The PCR program used was: 1)
95 °C, 5 minutes and 2) 95 °C 10 s, 60 °C 10 s, 72 °C 10 s,
with 45 cycles.
An aliquot of these samples was analyzed by western
blot. Protein concentrations were evaluated using the Brad-
ford method and adjusting protein concentration to 1 μg/
μl: 20 μg of each individual sample was separated by 15 %
SDS-PAGE and transferred onto nitrocellulose membrane.
The membranes were blocked with 5 % milk and probed
with anti-IL-17 (1:2,000) (Abcam, Inc. Cambridge, MA,
USA) and visualized using a horseradish-peroxidase-linked
secondary antibody and Amersham ECL prime Western
blotting Detection Reagent (GE Healthcare, Pittsburgh, PA,
USA). GAPDH (Abcam) was used as a loading control.ivary gland of Aec1/Aec2 mice. a Relative mRNA levels of the IL-17R:Fc
rus vector (1E7, n = 4, 1E8, n = 5, 1E9, n = 5) or ultrasound-assisted
mean. b Western blot analysis of salivary gland tissue treated with
. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a
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At 48 hours after gene transfer animals were sacrificed
and blood collected by cardiac puncture. Serum IL-17
concentrations were determined by the Bio-Plex Pro™
Assay (Bio-Rad, Hercules, CA, USA).
Proteomic profiling of salivary glands
Animals were sacrificed 21 days after gene transfer (to
mimic the optimal functional improvements observed by
Nguyen et al. [7]) by cervical dislocation and subman-
dibular glands removed and homogenized on ice using
2D lysis buffer (7 M Urea, 2 M Thiourea, 2 % CHAPS).
Samples were cleaned using a 2-D Quant kit (GE
Healthcare) and resuspended in 2D gel rehydration buf-
fer (7 M Urea, 2 M Thiourea, 2 % CHAPS) containing
50 mM Tris pH8.5. Protein concentrations were deter-
mined using the Bradford method and adjusted to 1 μg/μl.
Profiling was performed initially on pooled samples (n =
animals/group): 1 μl of Cy2, Cy3 or Cy5 were added to
50 μg of each pooled group sample respectively. Three
gels were performed with dye swapping, to ensure that
each pooled group was labeled with each Cy dye. After
addition of dye, samples were incubated on ice for 30
minutes in the dark. After 30 minutes, 1 μl of 10 mM
lysine was used to quench the reaction by incubating
on ice for 10 minutes in the dark.
Isoelectric focusing (IEF) and SDS electrophoresis
were performed as we have previously described [12].
Briefly, 15 μg of each labeled sample was diluted inFig. 2 Relative serum levels of IL-17 in Aec1/Aec2 animals treated with gen
via cardiac puncture 48 hours after gene transfer to the submandibular gla
(1E7, n = 11, 1E9, n = 4). Error bars are + standard error of the mean. *Signific
ultrasound-assisted gene transfer (UAGT)/IL-17R:Fc (n = 10). **Significant differrehydration buffer to 450 μl for IEF. A 24-cm strip,
pH3-10NL was rehydrated by adding 2 % DTT, 0.5 %
IPG buffer and 0.002 % bromophenol blue room
temperature for 8 hours. Samples were applied to rehy-
drated strips and loaded onto an Ettan IPGphor 3. IEF
was performed overnight for 60,000 volt-hours (vhr).
The next day, the strips were equilibrated with 1 % DTT
followed by 2.5 % iodoacetamide for 15 minutes each
and separated in a 13.5 % SDS gel. Finished gels were
scanned on a Typhoon Trio (GE Healthcare). The pic-
tures were edited using ImageQuant TL 7.0 software
(GE Healthcare). Differential in-gel analysis (DIA) and
biological variation analysis (BVA) of the two-
dimensional differential gel electrophoresis (2D DIGE)
results were performed using DeCyder 2D 7.0 Software
(GE Healthcare).
Pairwise comparisons
In order to confirm the statistical validity of spots of
interest identified by DIA analysis, pairwise comparisons
of the various groups were made to allow BVA. Pairwise
comparisons were performed on randomly paired indi-
vidual samples from each group labeled respectively with
Cy3 or Cy5 or vice versa and using a mixed sample la-
beled using Cy2 as an internal standard.
Phosophoprotein staining
In order to determine the phosphorylation of spots 4
and 5, 2-D gels were run (as described above) with ae transfer to the salivary glands. Plasma was collected from animals
nds. Dosages of adenoviral vector are expressed as viral particles/gland
ant difference (p <0.05) between negative control (AdLuc, n = 9) and

















































Fig. 3 Proteomic profiling of mouse submandibular glands 21 days after
gene transfer. a Fluorescent intensity map generated as an average of
three gels, with rotation of Cy2, Cy3, and Cy5 dyes between the three
pooled samples (n = 5/group). b Annotation of the intensity map shown
in 3a. UAGT ultrasound-assisted gene transfer, Luc Luciferase
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and stained with Pro-Q Diamond phosphoprotein gel
stain reagent for phosphorylated protein. The locations
of spots 4 and 5 were identified using landmarks, and
the gels were washed and stained with Sypro Ruby for
total protein. Spots 4 and 5 were then cut from the gel
and protein ID performed to confirm their identity. Both
reagents were obtained from Thermo Fisher Scientific
Inc. Waltham, MA USA.
Protein identification
Protein identification was performed as previously de-
scribed [13]. Briefly, protein spots of interest were ex-
cised from the 2-D gel, reduced by DTT, alkylated with
iodoacetamide, digested with trypsin and desalted with
C18 ZipTips (Millipore Corporation, Billerica, MA,
USA). Both mass spectrometry (MS) and tandem mass
spectrometry (MS/MS) analyses of the digested peptides
were performed on the matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-
TOF)/TOF tandem MS (Bruker UltrafleXtreme MALDI
TOF/TOF Mass Spectrometer, Bruker Daltonics Inc.
Billerica, MA, USA). The database search and analysis
were performed using FlexAnalysis and BioTools soft-
ware (Bruker Daltonics Inc.) against mouse Swiss-Prot
protein database using a local Mascot search engine.
Statistical analysis
Group comparisons in Figs. 1a and 2 were made using
the Mann-Whitney U test. Analysis of proteomic profiles
was performed within the DeCyder software, with 2-fold
changes as the threshold. DIA was used for pooled gels
and BVA was used for pairwise comparisons. In all cases,
statistical significance was considered to be p <0.05.
Results
Ultrasound-assisted gene transfer of the IL-17R:Fc cDNA
results in expression levels of the fusion protein comparable
to previously reported doses of adenovirus and reduces
IL-17 protein to background strain levels
IL-17R:Fc expression from 1 × 107 vp of Adenovirus has
previously been reported to be sufficient for gene ther-
apy efficacy in the Aec1/Aec2 mouse model [7]. We first
sought to compare IL-17R:Fc mRNA expression levels
after UAGT relative to the 1 × 107 dose as well as the
higher doses (1 × 109−1 × 1010vp) that have been more
commonly reported in the salivary gland gene therapy
literature. Figure 1a shows relative mRNA levels from
Aec1/Aec2 mouse submandibular glands 48 hours after
gene transfer of IL-17R:Fc delivered by UAGT, 1 × 107
vp, and 1 × 109 vp of adenovirus. AdLuc gene transfer in
the Aec1/Aec2 mice served as a negative control.
In order to demonstrate the functionality of IL-17R:Fc
for reducing IL-17 protein in salivary gland tissue, we
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48 hours after UAGT/IL-17R:Fc, with UAGT/Luc serv-
ing as a negative control and the background strain serv-
ing as a positive control (Fig. 1b). These experiments
demonstrated that IL-17 is highly expressed in the saliv-
ary glands of the Aec1/Aec2 mouse relative to the back-
ground strain, and that this increase is dramatically
reversed by IL-17R:Fc gene transfer.
IL-17R:Fc expression in the salivary gland of Aec1/Aec2
mice at 8 weeks of age significantly lowers serum IL-17
As an additional assurance that IL-17 levels were re-
duced by our gene therapy, we assayed serum levels of
IL-17. Nguyen et al. previously reported that IL-17R:Fc
gene therapy significantly reduces IL-17 levels systemic-
ally, although it is unknown whether this is due solely to
local sequestration of IL-17 in the salivary gland, or
whether IL-17R:Fc is secreted into the blood from the
salivary gland. Blood was collected from the same ani-
mals studied in Fig. 1a and b and relative serum IL-17
levels were assayed, with results shown in Fig. 2. These
results confirmed that our IL-17R:Fc was working as
intended, and allowed us to move forward into prote-
omic profiling of the therapeutic effect.
IL-17R:Fc expression in the salivary glands of Aec1/Aec2
mice suppresses expression and/or post-translational
modification of disease-associated proteins, including the
putative autoantigen Klk1b22
We performed difference gel electrophoresis on pooled
samples of submandibular gland lysates from the three
treatment groups (UAGT/IL-17R:Fc, UAGT/Luc, and
background strain) 21 days after treatment, running all
three pooled samples on the same gels (three gels were
performed, to allow for swapping of the Cy dyes betweenTable 1 Protein identities of spots meeting the criteria of being associa
strain and being modified toward background strain levels as a result o
Spot number Protein identity
Disease-associated proteins, putative therapeutic targets of IL-17R:Fc (RED)
1 Unidentified









SS Sjrogen’s syndrome, UAGT ultrasound-assisted gene transfer, Luc Luciferasegroups) to generate aligned differential proteomic pro-
files as shown in Fig. 3a, and annotated in Fig. 3b. This
analysis design allowed us to parse out the proteomic
profile of the Aec1/Aec2 SS-like disease process (by
comparing background strain to UAGT/Luc-treated),
then to evaluate the effect of IL-17R:Fc treatment upon
this process (by evaluating the effect of UAGT/IL17R:Fc
treatment upon this dataset). Bioinformatic analysis, and
post-hoc pairwise comparisons, as described in Methods,
was undertaken to evaluate the statistical power of spots
shown to be differentially expressed between the treat-
ment groups.
They key findings of our proteomic analysis are anno-
tated in Fig. 3b and summarized in Table 1. These pro-
teins met the dual criteria of 1) being disease-associated
and 2) being modulated toward background strain ex-
pression levels by IL-17R:Fc, and were thus designated
as putative therapeutic targets of IL-17R:Fc gene therapy
treatment. Suppression of local IL-17 expression was
verified at the 21 days post-treatment time point (see
Figure S1 in Additional file 1).
Most notably, Il-17R:Fc gene therapy dramatically re-
duced expression of Klk1b22, which has been shown to
be sufficient to cause keratoconjunctivitis sicca (KCS)
when used to inoculate healthy Lewis rats [14]. Because
a reliable antibody is not available for detecting mouse
Klk1b22, we have provided sequence coverage obtained
from spots 9 and 10 in Fig. 4a, demonstrating that we
can make this identification with high confidence. Rela-
tive levels of Klk1b22 and Kallikrein-1 isoforms in the
salivary glands of the background strain and treatment
groups are illustrated graphically in Fig. 4b. Kallikrein-1
has been implicated as an autoantigen in the IQI/Jic
mouse model of SS [15], and earlier studies associated sia-
lylation of tissue Kallikreins with autoimmune diseasested with SS-like disease in the Aec1/Aec2 model versus background
f IL-17R:Fc gene therapy
Peak volume














Fig. 4 (See legend on next page.)
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Fig. 4 Identification and relative quantification of the putative biomarkers Kallikrein-1 and Klk1b22 after treatment with IL-17R:Fc gene therapy.
a Mass spectrometry sequence coverage of spots 6, 9 and 10 identified as Klk1b22. b Gel imaging shown in Fig. 3 was subjected to relative
quantitative analysis to measure fluorescent intensity of spots positively identified to be Kallikrein-1 (4 and 5) or Klk1b22 (6, 9, and 10). Numerical
values of these intensities are shown in Table 1. c Magnification of 2-D gels run with either ultrasound-assisted gene transfer/Luciferase (UAGT/
Luc) or UAGT/IL-17R:Fc samples, showing total Kallikrein-1 (KLK1, top bars) and phosphorylated Kallikrein-1 (bottom bars). Acidic shift of KLK1 is
attributed to phosphorylation
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Kallikrein-1 might be attributable to phosphorylation
and Fig. 4c shows phosphoprotein staining of spots 4
and 5 with UAGT/Luc versus IL-17R:Fc treatment,
strongly suggesting that IL-17R:Fc gene therapy enhances
the phosphorylation state of Kallikrein-1, although not to
background strain levels.
IL-17R:Fc expression in the salivary glands of Aec1/Aec2
mice broadly suppresses expression of Kallikrein1-related
peptidases
The proteome of the submandibular gland of the Aec1/
Aec2 mouse, and that of the C57/BL6 background strain
upon which it is based, is characterized by strong ex-
pression of highly basic, low molecular weight Kallikrein
1-related peptidases (yellow boxes in Fig. 3b, and
Table 2). These peptidases are not associated with the
SS-like disease in the Aec1/Aec2 mouse, but are broadly
downregulated by IL-17R:Fc treatment. Taken together
with the preceding results, it appears that the effects of
IL-17 sequestration on Klk1-related peptidases are rela-
tively unspecific. Table S1 (in Additional file 2), catalogs
all proteins identified to be significantly different be-
tween UAGT/Luc and UAGT/IL-17R:Fc-treated salivary
glands.
Discussion
The presence of IL-17-expressing T cells, both CD4+/CD8−
and CD4−/CD8− [18], in the salivary glands is strongly
associated with SS in human biopsies and animal modelsTable 2 Protein identities of spots of interest that did not meet
our criteria for disease/therapy-associated biomarkers
Spot number Protein identity
Proteins modulated by gene transfer (GREEN)
Green box Renin 1,2 unidentified
11 Renin 1,2
Disease-associated proteins unaffected by IL-17R:Fc (BLUE)
12 Klk1b6/b26
Proteins unassociated with disease, but modulated by IL-17R:Fc
(YELLOW)
Small box Klk1b16, Hemoglobin subunit beta 1, unidentified
Large box Klk1b6/b26, Klk1b8/b26, Klk1b21/b24, Klk1b8/b16/b26,
Hemoglobin subunit alpha, Klk1b9, Klk1b3/b6/b9/b11
13 Klk1b5[19–22]. These clinical findings amplify the translational
potential of IL-17-blocking gene therapy and the potential
relevance of the Aec1/Aec2 mouse model to under-
standing the molecular choreography of SS. With evi-
dence accumulating that local expression of IL-17 in
the salivary gland plays a detrimental role in the initiation
and/or progression of SS [23], further focus on IL-17 se-
questration, either through conventional pharmacotherapy
(e.g., anti-IL-17 monoclonal antibodies) or gene therapy
(e.g., IL-17R:Fc), appears promising.
Nguyen et al. [7] previously showed impressive thera-
peutic effects of IL-17R:Fc gene therapy in the Aec1/
Aec2 mouse model, including functional, histological,
and serological metrics of benefit. Our study adapted
UAGT, a safe and clinically promising method of deliver-
ing IL-17R:Fc gene therapy without the immunogenic
consequences of the adenoviral vector. By using this im-
munologically compatible approach, we can parse out
the molecular consequences of IL-17R:Fc gene therapy
in the salivary glands of this animal model, using the
non-disease-prone background strain as an additional
means of inferring putative disease relevance of proteins
affected by IL-17 and its inhibition.
Our results provide additional momentum for the idea
that IL-17R:Fc gene therapy may be a viable means of
inhibiting IL-17 locally within the salivary gland. We
achieved IL-17R:Fc expression levels equal to or greater
than those needed to achieve therapeutic efficacy, with-
out the need for a viral vector. We did not explore the
duration of transgene expression in great detail, but have
previously reported that UAGT drives transgene expres-
sion for several weeks in the salivary gland of mice [10]
and have recently observed similar results in mini-swine
[24]. This technique is minimally invasive and should be
repeatable on an outpatient basis if extended therapy is
required.
Our finding that IL-17 inhibition is most strongly
associated with suppression of Klk1b22, a Kallikrein
1-related peptidase, is novel and may provide clues into
the propagation of SS in salivary glands where IL-17-
producing cells are resident. Little is known about the
function of Klk1b22, and while it was originally believed
to be an EGF-binding protein (EGF-BP) [25, 26], later
studies demonstrated a lack of EGF binding and rather
an ability to cleave Nerve Growth Factor [27]. It is there-
fore possible, although unproven, that Klk1b22 and
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gamma. Very recently, Jiang et al. [14] showed that
Klk1b22, expressed as a recombinant protein, can induce
SS-like experimental autoimmune KCS in otherwise
healthy Lewis rats, a strain of animals not prone to SS-
like disease. This followed an earlier report that the tis-
sue kallikrein Klk-13 acts as an autoantigen to stimu-
late SS-like disease in the IQI/Jic mouse model [15].
Our study provides further evidence that Klk1b22 may
be a molecular antigen responsible for the well-established
phenomenon of inducible SS-like disease, where immu-
nization of healthy animals with salivary gland or lacrimal
gland extracts leads to the development of KCS [28–30].
Notably, the gene for Klk1b22 is on Chromosome 7, and
thus not directly related to the Aec1 (Chromosome 3) and
Aec2 (Chromosome 1) alleles responsible for SS-like dis-
ease in this animal model. Gene expression of the develop-
ing lacrimal gland in this mouse model has been
characterized and includes differential expression of tissue
kallikreins although Kallikrein-related peptidases were not
mentioned [31].
To our knowledge, this is the first study suggesting a
causal link between local IL-17 in the salivary gland and
tissue levels of Klk1b22. While the expression levels of
numerous molecules have been shown to be induced by
IL-17, Kallikreins and Kallikrein-related peptidases are
not among the known IL-17 inducible molecules al-
though a recent study suggested an expanded range of
gene expression downstream of IL-17 in keratinocytes
that includes Klk1b6, Klk1b10, and Klk1b13 [32]. Our
results suggest a causal link between IL-17 and tissue
levels of Klk1b22, but the proximity of the cause and ef-
fect is as yet unknown, and could be remote. If Klk1b22
expression is indeed an autoantigen capable of inducing
KCS, and this mechanism has any relevance to human
SS, IL-17 could represent a therapeutic target upstream
of irreversible glandular damage.
Many questions remain unanswered by our limited
study. Beyond the obvious need for vetting the relevance
of Klk1b22 to human SS, key questions to be addressed
in future studies are 1) whether IL-17 sequestration can
reverse Klk1b22 expression that is already manifest, and 2)
whether systemic antagonism of IL-17, such as with the
newer monoclonal antibodies Secukinumab and Izekizu-
mab, leads to the same local suppression of Klk1b22 in the
salivary gland, and 3) whether IL-17 blockade ablates pro-
duction of anti-Klk1b22 autoantibodies. Given the indo-
lent and progressive course of SS, there is some reason for
hope that the window for blocking the biochemical cas-
cade leading to tissue destruction may be wide.
Conclusions
Non-viral IL-17 sequestration gene therapy in the salivary
gland is feasible and downregulates expression of aputative SS autoantigen in the Aec1/Aec2 mouse. Based
upon our results, further exploration of the therapeutic
potential of IL-17 sequestration in Sjogren’s syndrome,
either through gene therapy or biopharmaceuticals, is
warranted.
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